$1.72 Billion in Sales Expected for Chemours Co (CC) This Quarter
Wall Street brokerages forecast that Chemours Co (NYSE:CC) will post sales of $1.72 billion for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Chemours’ earnings. The lowest sales estimate is $1.71 billion and the highest is $1.72 billion. Chemours reported sales of $1.58 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 8.9%. The firm is scheduled to announce its next quarterly earnings results after the market closes on Thursday, November 1st.
On average, analysts expect that Chemours will report full year sales of $6.95 billion for the current financial year, with estimates ranging from $6.90 billion to $7.06 billion. For the next financial year, analysts expect that the company will post sales of $7.23 billion, with estimates ranging from $7.03 billion to $7.49 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Chemours.
Chemours (NYSE:CC) last issued its earnings results on Thursday, August 2nd. The specialty chemicals company reported $1.71 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.18. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.82 billion. Chemours had a return on equity of 107.22% and a net margin of 15.11%. The firm’s quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS.
Several large investors have recently bought and sold shares of the company. Cornerstone Wealth Management LLC grew its position in shares of Chemours by 22.4% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 19,460 shares of the specialty chemicals company’s stock valued at $355,000 after acquiring an additional 3,560 shares during the period. Seven Eight Capital LP acquired a new stake in shares of Chemours during the 3rd quarter valued at about $2,125,000. First American Bank acquired a new stake in shares of Chemours during the 3rd quarter valued at about $268,000. Andra AP fonden grew its position in shares of Chemours by 16.2% during the 3rd quarter. Andra AP fonden now owns 131,300 shares of the specialty chemicals company’s stock valued at $5,178,000 after acquiring an additional 18,300 shares during the period. Finally, Polianta Ltd grew its position in shares of Chemours by 17.7% during the 3rd quarter. Polianta Ltd now owns 27,900 shares of the specialty chemicals company’s stock valued at $1,100,000 after acquiring an additional 4,200 shares during the period. Hedge funds and other institutional investors own 76.68% of the company’s stock.
CC stock traded up $0.25 during midday trading on Thursday, reaching $35.87. The stock had a trading volume of 1,345,242 shares, compared to its average volume of 1,690,724. The firm has a market capitalization of $6.34 billion, a price-to-earnings ratio of 9.39, a price-to-earnings-growth ratio of 0.41 and a beta of 2.75. The company has a debt-to-equity ratio of 3.86, a current ratio of 2.09 and a quick ratio of 1.47. Chemours has a 52-week low of $34.84 and a 52-week high of $58.08.
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
Featured Article: Average Daily Trade Volume – ADTV
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.